Turning Pennies into dollars:(OTCBB:IXSBF) InNexus Biotechnology Inc
Are you a public company looking for exposure?
Contact RealPennies.com - 212-662-2147
For more info: http://www.realpennies.com/otc/ixsbf
InNexus Biotechnology CEO to Present at the 11th Annual BIO CEO Conference
(OTCBB:IXSBF) InNexus Biotechnology Inc.
Wednesday February 4, 9:02 am ET
BRITISH COLUMBIA, Canada, Feb. 4 /CNW/ - InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX Venture: IXS.V; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking ) technology, announces Jeff Morhet, Chairman and CEO, will be presenting at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 10:30-10:55 AM ET in the Park Ballroom at the Waldorf-Astoria in New York City.
Mr. Morhet will provide a brief corporate overview; discuss the company's growth and how its antibody enhancement technology improves the potency of existing and novel therapeutic products. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the symposium.
About BIO CEO The 11th Annual BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies. The conference provides a neutral forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts have the opportunity to shape the future investment landscape of the biotechnology industry.
About InNexus InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.
For further information
Wade Brooksby, Chief Financial Officer, InNexus Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com
Profile for InNexus Biotechnology Inc.
InNexus Biotechnology, Inc., a drug development company, focuses on commercializing monoclonal antibodies based on its Dynamic Cross Linking technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company was founded in 2001 and is headquartered in Vancouver, Canada. Detailed IXSBF Company Description...
LAST $0.11 USD
Realpennies.com
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on
http://www.realpennies.com/start.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.
RealPennies.com
Phone: 212-662-2147
info [at] realpennies.com
No comments:
Post a Comment